Skip to main content
. 2018 Dec 3;62(7):274–280. doi: 10.3345/kjp.2018.06842

Fig. 3.

Fig. 3.

Sequential changes in insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) during growth hormone (GH) treatment in patients with Noonan syndrome, including the PTPN11, FGU, RAF1, and SOS1 groups. The Wilcoxon signed-rank test was used to compare the responses to GH therapy according to the disease-causing genes. The serum IGF-1 SDS levels in the FGU group were significantly elevated after 3 years of GH therapy compared with the other groups. *P<0.05.